PD-L1 expression testing in lung carcinoma prior to pembrolizumab therapy (Dako PD-L1 IHC 22C3 PharmDX kit)
PD-L1 is an immune-related biomarker that can be expressed on tumour cells.
Evaluating PD-L1 expression level at diagnosis of NSCLC contributes to a better understanding of your patient’s tumour and helps inform treatment decisions.
Lab 21 is currently offering a service based on the Dako PD-L1 22C3 pharmDx kit, it is a qualitative assay for use in the detection of PD-L1 in formalin fixed, paraffin-embedded (FFPE) in non – small cell lung carcinoma.
To request PD-L1 testing, please contact the Lab 21 Customer Services Team for further information regarding requesting the test and pricing.